GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. (Q38055195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mikkel Christensen

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Maria J Jespersen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

24 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

17-29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23094590%20AND%20SRC:MED&resulttype=core&format=json

The Physiology of Glucagon-like Peptide 1

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Incretin-based therapy and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Intestinal sensing of nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

TGR5-mediated bile acid sensing controls glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Incretin and islet hormonal responses to fat and protein ingestion in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Nutrient, neural and endocrine control of glucagon-like peptide secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Endoproteolysis of glucagon-like peptide (GLP)-1 (7-36) amide by ectopeptidases in RINm5F cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

What do we know about the secretion and degradation of incretin hormones?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Investigation of exenatide elimination and its in vivo and in vitro degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effect of renal impairment on the pharmacokinetics of exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effect of exenatide on the steady-state pharmacokinetics of digoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Exenatide efficacy and safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

GLP-1-based therapies: the dilemma of uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

GLP-1-based therapies and the exocrine pancreas: more light, or just more heat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Investigation of the haemodynamic effects of exenatide in healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Temporal changes in resting heart rate and deaths from ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide: short-lived effect on gastric emptying -- long lasting effects on body weight.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

The alpha-cell as target for type 2 diabetes therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Anorexigenic effects of GLP-1 and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.731394